Barclays initiated coverage of Summit Therapeutics (SMMT) with an Underweight rating and $13 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics falls -24.1%
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX